Jonathan Slonin is Chief Medical Officer at Pacira BioSciences, Inc. (PCRX). They have made 4 open-market trades across 1 company since 2022, most recently 2026-08-17.
CIK 0001875723
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCRX | 216,383 | $7.9M |
Shares reported on the most recent Form 4, priced at the 2026-08-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCRX | SELL · 10b5-1 | 2026-08-17 | 2026-08-18 | $23.23 | $71K | +6.2% | +1.0% | — |
| PCRX | SELL · 10b5-1 | 2026-03-17 | 2026-03-19 | $22.82 | $74K | -0.7% | +9.5% | -0.6% |
| PCRX | SELL · 10b5-1 | 2025-11-17 | 2025-11-19 | $24.09 | $191K | -2.0% | +7.3% | -7.4% |
| PCRX | SELL · 10b5-1 | 2025-01-06 | 2025-01-06 | $18.40 | $16K | +18.9% | +44.1% | +21.9% |
| PCRX | SELL · 10b5-1 | 2024-08-02 | 2024-08-02 | $20.05 | $19K | -38.2% | -24.8% | -17.8% |
| PCRX | SELL · 10b5-1 | 2024-07-02 | 2024-07-03 | $28.25 | $80K | -1.0% | -1.5% | -29.1% |
| PCRX | SELL · 10b5-1 | 2024-06-11 | 2024-06-13 | $28.57 | $286K | -1.0% | -23.7% | -53.4% |
| PCRX | SELL | 2023-06-06 | 2023-06-07 | $38.42 | $37K | +9.4% | +1.4% | -7.0% |
| PCRX | SELL | 2022-08-03 | 2022-08-05 | $55.70 | $17K | -0.7% | -12.5% | -15.3% |
| PCRX | SELL | 2022-07-05 | 2022-07-07 | $57.19 | $106K | -6.1% | +1.4% | -2.0% |
| PCRX | SELL | 2022-06-06 | 2022-06-08 | $61.37 | $22K | -9.5% | -2.7% | -12.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.